|
Novel Pharmaceutical for Prevention of Bleomycin-Induced Pulmonary Fibrosis
Reference #: 01409
The University of South Carolina is offering licensing opportunities for Novel Pharmaceutical for Prevention of Bleomycin-Induced Pulmonary Fibrosis
Background:
Hodgkin’s lymphoma is one of the curable cancers and the standard treatment regimen involves combination chemotherapy involving bleomycin. One of the fatal side effects...
Published: 9/4/2022
|
Updated: 5/13/2021
|
Inventor(s): Michael Wyatt, Chloe LeBegue
Keywords(s): bleomycin, bleomycin hydrolase, enzyme, inhaled, protein, pulmonary fibrosis, pulmonary toxicity, pulmonology biotech, pulmonology pharma
Category(s): Chemistry and Biochemistry, Health Sciences
|